Advertisements



We are Sorry, This Page doesn't Exist


Roche"s Tecentriq Met Primary Goal in First-Line NSCLC Study

Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS). Roche H.....»»

Category: dealsSource: nytJul 19th, 2018

Brainstorm Health: Puerto Rico Maria Deaths, Roche Lung Cancer Drug, Planned Parenthood Setback

Brainstorm Health Daily: May 29, 2018 Hurricane season does not officially begin until Friday, June 1--though that start date is somewhat artificial as Subtropical Storm Alberto made clear yesterday--driving its way across .....»»

Category: europeSource: fortuneMay 29th, 2018

Biopharmaceutical company fined for misleading investors

A Colorado-based biopharmaceutical company has been penalized more than $20 million for misleading investors about the efficacy of a lung cancer drug under development before raising $300 million in a public stock offering......»»

Category: topSource: foxnewsSep 19th, 2018

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

Clovis shares might not be showing it now, but the company is facing some heat from the SEC over charges of misleading investors about the company’s developmental lung cancer drug......»»

Category: blogSource: 247wallstSep 19th, 2018

Bristol-Myers" Opdivo Gets FDA Nod for Small Cell Lung Cancer

Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cance.....»»

Category: topSource: zacksAug 20th, 2018

Bristol-Myers wins FDA approval for Opdivo as treatment for small cell lung cancer

Bristol-Myers Squibb Co. said Friday the U.S. Food and Drug Admi.....»»

Category: topSource: marketwatchAug 17th, 2018

Roche Hiked Cancer Drug Price Before Empty Promise To Keep Flat

Swiss drugma.....»»

Category: blogSource: zerohedgeJul 21st, 2018

Bristol-Myers Posts Data on Empliciti, China Approves Opdivo

Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer. Br.....»»

Category: dealsSource: nytJun 18th, 2018

Lung Cancer Drug From Merck Solidifies Lead in Crowded Field - Bloomberg

KDALLung Cancer Drug From Merck Solidifies Lead in Crowded FieldBloombergIn the race to.....»»

Category: topSource: googlenewsJun 3rd, 2018

Pfizer"s Xalkori Gets Breakthrough Status for New Indications

Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications. Pfi.....»»

Category: dealsSource: nytMay 30th, 2018

Roche Won"t Go Down Without A Fight In The Front-Line Lung Cancer Space

Roche Won"t Go Down Without A Fight In The Front-Line Lung Cancer Space.....»»

Category: topSource: seekingalphaMay 30th, 2018

Roche"s Tecentriq Study Meets Co-Primary Endpoints for NSCLC

Roche's (RHHBY) Tecentriq meets its co-primary endpoints of overall survival and progression-free survival in a phase III study for lung cancer. Roche RHHBY announced that the phase III study, IMpower130 on immunot.....»»

Category: smallbizSource: nytMay 29th, 2018

AstraZeneca"s drug extending survival rate in lung cancer patients

Using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity.....»»

Category: topSource: business-standardMay 26th, 2018

No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says

Treating breast-cancer patients with an expensive Roche drug for six months instead of 12 reduced heart-related side effects without sacrificing effectiveness, a new study found......»»

Category: smallbizSource: wsjMay 16th, 2018

Exelixis, Roche slide after colon cancer drug fails to meet primary study goal

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 10th, 2018

Immune therapy doubles lung cancer survival rate

New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found.....»»

Category: topSource: bizjournalsApr 17th, 2018

New Drug Combinations Improve Survival in Lung Cancer

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

Category: smallbizSource: wsjApr 17th, 2018

Brainstorm Health: Merck’s Lung Cancer Triumph, COPD and Women, Trump on Drug Prices

Brainstorm Health Daily: April 16, 2018 Hello and happy Monday, readers! This is Sy. New study results released Monday continue to cement drug giant Merck’s status as the force to be r.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck shares rise after beating rivals" lung cancer results

In a fierce rivalry to prove cancer drug combinations work better for advanced.....»»

Category: topSource: marketwatchApr 16th, 2018

This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock Soaring

Merck gained.....»»

Category: europeSource: fortuneApr 9th, 2018